PCR Machines

ResearchDx is a comprehensive diagnostic development and contract research organization (CRO) specializing in in vitro diagnostic (IVD) test development, validation, and commercialization. The company operates three integrated divisions: Contract Services (biomarker discovery, assay development, regulatory filings); Diagnostic Laboratory (CLIA/CAP/ISO 15189 accredited clinical testing under the PacificDx brand); and Diagnostic Manufacturing (ISO 13485:2016 and GMP-compliant kit manufacturing under the CustomDx brand). Core capabilities include custom molecular assay development (PCR, qPCR, ddPCR, NGS, microRNA, protein, flow cytometry, ELISA), analytical and clinical validation, companion diagnostic development, and complete laboratory accreditation consulting. The company is ISO 13485:2016 certified, CLIA approved, CAP accredited, and FDA registered. Recent achievements include FDA 510(k) clearances for GlutenID celiac genetic health risk test and regulatory approvals for companion diagnostics (ProMarkerD for diabetic kidney disease, FibroSIGHT for MASH liver fibrosis detection). ResearchDx serves pharmaceutical companies, diagnostic startups, and established laboratories requiring integrated IVD development from concept through commercialization and contract manufacturing.

Integrated DNA Technologies (IDT) is a life sciences research reagents and molecular biology tools supplier headquartered in Coralville, Iowa. The company manufactures custom DNA and RNA oligonucleotides, primers, probes, and gene fragments for research applications. IDT's product portfolio includes custom DNA/RNA oligos with rapid turnaround (>90% of standard orders within 24 hours, quality-checked by ESI-MS); Ultramer oligos; oligo pools; SameDay and Rapid HPLC oligo services; modified nucleotides and linkers; qPCR/dPCR probes and assays under the PrimeTime trademark; PCR primers and master mixes; CRISPR-Cas9 and CRISPR-Cas12a systems with guide RNAs, libraries, and enzymes; gene synthesis and gBlocks HiFi gene fragments (NGS-verified); next-generation sequencing (NGS) library preparation kits (DNA, RNA, methyl-seq), hybridization capture panels, amplicon panels, and library normalization tools under the xGen brand; Archer Anchored Multiplex PCR sequencing assays for oncology, infectious disease, and liquid biopsy applications; gene regulation products including RNAi, antisense oligonucleotides, and miRNA inhibitors; GMP oligo and CGMP CRISPR manufacturing for therapeutic development; and OEM services including custom assay development, integrations, APIs, PAGE/HPLC purification, and formulation/packaging. IDT serves academic research, diagnostic development, and therapeutic development markets. The company emphasizes rapid turnaround, quality control, and regulatory compliance in manufacturing.

DTPM INC. is a laboratory solutions distributor and service provider serving physician offices, reference labs, recovery courts, and treatment centers across 47 US states since 1993. The company provides turnkey laboratory solutions including testing equipment, consumables, reagents, and comprehensive lab management services. DTPM offers an FDA EUA-authorized COVID-19 RT-PCR assay validated for detection of multiple SARS-CoV-2 variants including delta and omicron strains. The company distributes Solstice Advanced Materials (formerly Honeywell Research Chemicals) products including DNA/RNA purification kits applicable to bacterial, viral, and fungal samples, as well as complex matrices such as buccal swabs, saliva, respiratory samples, and blood. DTPM FreeWipes are single-ply, lint-free laboratory wipes available in bulk quantities. The company operates an online store offering analyzer consumables, collection supplies, laboratory chemicals, equipment, and general supplies from multiple manufacturers. DTPM has developed over 150 molecular assays and employs staff with 26+ years of laboratory setup experience and 30+ years of research expertise. Services include total program management for labs, dedicated technical support, point-of-care training and certification, and laboratory information systems (LIS) with online data and results management capabilities. The company focuses on high-volume routine and specialty testing, drug testing coordination with recovery and treatment programs, and customized solutions for various laboratory settings.

Randox Laboratories is a global leader in diagnostic solutions with over 40 years of expertise in clinical laboratory, molecular, and point-of-care diagnostics. The company manufactures a comprehensive portfolio including the RX Series clinical chemistry analyzers, Vivalytic molecular point-of-care systems, and Evidence Series immunoassay analyzers. Randox provides open-channel reagents covering more than 100 disease areas including autoimmune disorders, cancers, and emergency/critical care diagnostics. The company operates as the world's largest external quality assessment (EQA) provider through RIQAS and QCMD platforms, serving over 100,000 users across 145 countries. Core offerings include quality control solutions (Acusera brand), third-party diagnostic assays, molecular infectious disease controls, and QC data management software. Beyond laboratory equipment, Randox operates multiple specialized service divisions: Contract Manufacturing (OEM partnerships), CDx and Biopharma services (biomarker development), Genomics (end-to-end sequencing with in-house bioinformatics), Pathology Services (sample collection and advanced testing), Toxicology (forensic drug detection for 600+ substances), Workplace Drug and Alcohol Testing, Food Diagnostics (antimicrobial and toxin screening), and Randox Health (preventative healthcare and home testing kits). The company serves clinical laboratories, reference labs, pharmaceutical companies, food/beverage industry, workplace testing, and forensic applications globally.

Theragenics Corporation is a global specialty medical device company founded in 1981 by physicists from Georgia Institute of Technology, headquartered in Buford, Georgia. The company specializes in commercial-scale radioisotope manufacturing and low-dose-rate (LDR) brachytherapy seeds for cancer treatment, with a vertically integrated operation managing isotope production, manufacturing, and global logistics. Theragenics operates a 134,000 sq ft radioisotope production facility with 14 cyclotrons enabling large-scale isotope production for therapeutic and diagnostic radiopharmaceuticals. The company's flagship brachytherapy products include TheraSeed® Palladium-103, AgX100® Iodine-125, and Cesium-131 seeds, along with innovative delivery systems such as preloaded needle trays, eye plaques, C20™ cartridges, AnchorSeed® encapsulated seeds, and stranded configurations. Theragenics also provides contract manufacturing services for radiopharmaceuticals and operates subsidiary companies offering interventional radiology and vascular surgery solutions. With over 40 years of excellence, the company has treated more than 271,000 patients worldwide and serves physicians and providers in over 40 countries, emphasizing precision, quality, and patient-centric innovation in minimally invasive cancer therapies.

Genesee Scientific LLC is a US-based distributor of laboratory equipment, consumables, and research supplies serving academic, clinical, and biotech laboratories. The company supplies a comprehensive portfolio of cell culture equipment, liquid handling systems, centrifugation equipment, sample agitation devices, and temperature control instruments from established brands including Poseidon, Benchmark, Eppendorf, Apex Bioresearch, FlyStuff, GenClone, Invictus, Next-Gen, Nutri-Fly, Olympus Plastics, and others. Product categories include cell culture equipment and cultureware, cell media, PCR reagents and consumables, nucleic acid extraction products, transfection reagents, liquid handling and pipette tips, tubes, centrifuges, incubators, drosophila-specific consumables and equipment, chemicals (acids, bases, solvents), gloves (including powder-free nitrile options), lab organization and storage solutions, and glassware. The company emphasizes reliable quality through curated product selection, exceptional cost efficiency via portfolio optimization, lab-centric solutions tailored to individual facility workflows, and support for scientific advancement. Genesee Scientific operates an e-commerce platform with account registration, personalized recommendations, promotional pricing programs, and order fulfillment. The company serves research institutions, academic labs, biotech firms, and clinical laboratories with consumables and equipment support.

Since 1986, Jant Pharmacal Corporation has been a leading B2B supplier of point-of-care (POC) diagnostic tests and laboratory instrumentation to U.S. and international healthcare settings. The company operates two primary divisions: POC Division and Lab Division. The POC Division offers CLIA-waived rapid tests and analyzers for use in physicians' offices, clinics, urgent care centers, and hospitals under registered trademarks Accutest, Accustrip, and LipidPlus. Product categories include cardiac testing, colorectal cancer screening, drugs of abuse, hypothyroidism, infectious diseases, pregnancy & fertility, and urinalysis. The Lab Division provides integrated solutions for laboratory optimization, featuring clinical chemistry, hematology, immunoassay, toxicology, urinalysis, and molecular diagnostic systems with reagents and consumables. The company holds GPO supplier contracts with Vizient and Champs, representing over 500,000 members. Additionally, Jant offers laboratory consultation services including financial feasibility assessment, turn-key laboratory setup, CLIA compliance consultation, LCMS method development, and laboratory information system integration.

Isla Lab Products, LLC is a Puerto Rico–based medical laboratory distributor and supplier founded in 1977 and expanded to the Caribbean in 2007. Headquartered at Amelia Industrial Park in Guaynabo, PR, the company operates a 30,000-square-foot facility with sales, customer service, technical and professional support, cold chain distribution, conference facilities, and a training center. The company distributes and supplies a comprehensive portfolio of clinical laboratory analyzers, reagents, consumables, and diagnostics across multiple specialties: clinical chemistry, immunochemistry, microbiology, hematology, transfusion medicine and blood banking, point-of-care testing, molecular diagnostics, pathology, toxicology, coagulation studies, COVID-19 testing, and rapid diagnostics. Key product offerings include automated chemistry analyzers (cobas® c 513, cobas® pure), microbiology identification and blood culture systems (VITEK® 2, BACT/ALERT® VIRTUO®, BACT/ALERT® 3D), rapid antigen testing platforms (Quidel Sofia 2), blood collection tubes (Vacuette®), and hematology analyzers (BC-5390). The company serves clinical laboratories, hospitals, diagnostic centers, and healthcare institutions across Puerto Rico and the Caribbean islands. Isla Lab Products maintains technical service capabilities, professional training, and cold chain logistics to support customer operations. The company operates as an authorized distributor for major in vitro diagnostics manufacturers and provides B2B procurement solutions for laboratory testing infrastructure and consumables.

Beckman Coulter Diagnostics is a global leader in clinical diagnostics and biomedical testing, headquartered in Brea, California. A subsidiary of Danaher Corporation since its foundational 1935 establishment, the company develops, manufactures, and distributes innovative laboratory automation systems, analyzers, and informatics solutions for clinical and research laboratories worldwide. The company specializes in clinical chemistry systems, immunoassay instruments, hematology analyzers, urinalysis systems, microbiology solutions, blood banking instruments, and protein chemistry platforms. Beckman Coulter also provides total lab automation systems (DxA 5000 series), advanced informatics middleware (Remisol Advance), and remote diagnostic services. Its comprehensive portfolio supports healthcare professionals and laboratory teams in disease diagnosis, treatment decisions, patient monitoring, and improved health outcomes. With annual revenue of approximately $2.9 billion, the company emphasizes efficiency, automation, clinical confidence, and integrated workflow solutions for hospital laboratories, reference laboratories, and blood banks globally.

Biobase Biodustry (Shandong) Co., Ltd is a high-tech manufacturer founded in 1999, headquartered in Jinan, Shandong, China. The company operates 25 manufacturing facilities and provides comprehensive one-stop solutions for laboratory, medical, and clinical applications. Core product categories include biological safety cabinets, laminar flow cabinets, fume hoods, sterilization equipment (autoclaves, sterilizers), clinical and analytical instruments (auto chemistry analyzers, electrolyte analyzers, blood bank refrigerators), flow cytometers, PCR cabinets, laboratory cryogenic refrigeration units, and hospital furniture (beds, wheelchairs). Biobase serves research institutions, clinical laboratories, diagnostic facilities, and healthcare providers across more than 190 countries. The company maintains in-house R&D (100+ employees), sales (200+ employees), and after-sales support teams (11+ employees). Certifications include ISO 9001, ISO 13485, ISO 14001, CE, FDA, NSF, SGS, and EN standards, reflecting compliance with international quality and medical device regulations. Services include 24-hour online customer support and warranty coverage for defective components.

IMMY is a US-based fungal diagnostics manufacturer and distributor founded in 1979, headquartered in Norman, Oklahoma. The company develops, manufactures, and distributes innovative diagnostic tests and reagents for fungal diseases affecting immunocompromised and critically ill patients. IMMY's product portfolio spans four core diagnostic platforms: (1) Lateral Flow Assays for rapid point-of-care testing (Cryptococcal Antigen, Aspergillus Galactomannan, Coccidioides Antibody); (2) Enzyme Immunoassays for high-volume laboratory settings (Histoplasma Galactomannan, Coccidioides Antibody, Blastomyces Antibody, Cryptococcal Antigen EIA); (3) Polymerase Chain Reaction assays for molecular detection of fungal pathogens (Candida auris, Candida species, Pneumocystis jirovecii); and (4) Traditional methods including Latex Agglutination, Cleargel™ Immunodiffusion, Complement Fixation, and MycoDDR specimen processing reagents. Products target endemic mycoses (histoplasmosis, coccidioidomycosis, blastomycosis, cryptococcosis) and emerging pathogens (Candida auris) in clinical reference laboratories, hospital microbiology departments, and HIV/AIDS care settings. IMMY reports impacting over 5 million lives annually, with products distributed in over 80 countries. The company operates with 100+ dedicated employees and maintains FDA clearance for its diagnostic assays. Regulatory status and ISO certifications not explicitly stated on homepage but implied through clinical adoption and international distribution.

Rainbow Scientific, Inc. (RSI) is a distributor of molecular cytogenetics, clinical chemistry, pathology, and hemostasis research laboratory products and solutions. The company specializes in providing state-of-the-art diagnostic and research reagents, including over 500 ready-to-use ASR goldFISH probes for hematology, pathology, prenatal, and molecular cytogenetic testing. RSI's product portfolio features high-performance fluorescence in situ hybridization (FISH) probes with flexible hybridization times, high signal-to-noise ratios, and low cross-reactivity. The company offers customizable FISH probe design, packaging, and fluorophore options to meet specific laboratory requirements. Additionally, RSI partners with Captivate Bio to distribute fetal bovine serum (FBS), cell culture media, and labware solutions to research and clinical laboratories. The company serves molecular and cellular research environments, clinical diagnostics laboratories, and pathology departments requiring reliable cytogenetic and molecular testing solutions.

DiaSorin Inc. is a global leader in laboratory diagnostics, specializing in immunodiagnostics and molecular diagnostics platforms. The company develops and manufactures diagnostic assays and analyzers for infectious diseases, immunological disorders, and other clinical applications. Core product lines include the LIAISON® automated immunoassay analyzer platform, Simplexa® molecular diagnostic kits for detection of viral pathogens (COVID-19, Flu A/B, RSV, HSV, CMV), and QuantiFERON® TB Gold Plus for tuberculosis detection. DiaSorin also offers the LIAISON® MeMed BV® for rapid bacterial-viral differentiation and LIAISON® BRAHMS PCT® for infection triage. The company operates the Luminex division, providing xMAP® multiplex assay technology platforms (xMAP INTELLIFLEX®) for biomedical research, clinical diagnostics, and drug discovery applications, including custom assay design and development services. Products address hospital laboratories, clinical diagnostic centers, and research institutions. The company maintains CLIA-waived status for certain molecular tests and holds FDA clearances and international regulatory approvals (CE marking). Manufacturing and distribution capabilities support North American and global markets.

Laguna Scientific is a laboratory equipment and consumables supplier specializing in molecular biology, cell culture, and sample preparation products. The company manufactures and distributes a comprehensive range of laboratory essentials including thermal cyclers (PCR equipment), shaking incubators, microcentrifuges, pipette tips in multiple volumes (10 µL, 1000 µL) with specialized formulations (RNase-free, DNase-free, endotoxin-free, PCR-inhibitor-free), microcentrifuge tubes, culture tubes with dual-position caps, multi-well cell culture plates (6-well, 12-well, 24-well, 48-well formats), and sterile cell strainers. Products are available in bulk and racked configurations to serve research institutions, clinical laboratories, biotech firms, and contract research organizations. The company emphasizes quality consumables with specifications suitable for sensitive applications such as PCR, qPCR, nucleic acid extraction, and cell culture work. Laguna Scientific operates as a direct-to-customer e-commerce supplier based in California, with capabilities to support high-volume laboratory operations.

Ansh Labs, a VION Biosciences company based in Webster, Texas, is a specialized biotechnology firm founded in 2010 that develops, manufactures, and distributes high-quality immunodiagnostic assays, reagents, and ELISA kits for biomedical research and clinical diagnostics. The company leverages in-house antibody development and characterization capabilities to create immunoassays targeting clinically significant biomarkers. Ansh Labs offers validated ELISA immunoassays with rapid turnaround times, high specificity, and excellent sensitivity—supporting 24-month shelf lives and straightforward procedures. Core service offerings include contract development of custom immunoassays, immunoassay method development and validation, assay optimization, cross-reactivity testing, and preclinical biomarker testing. The company serves life science researchers, hospitals, commercial laboratories, and public health agencies, with particular expertise in areas such as cancer diagnostics, fertility biomarker testing, obesity research, and specialty assays for glucagon regulation and reproductive health. Following its acquisition by VION Biosciences in August 2024, Ansh Labs continues to maintain its team and product portfolio while expanding its service capabilities.

C.R. Bard (now part of BD) is a diversified global medical technology company operating through multiple business segments: BD Interventional, BD Life Sciences, and BD Medical. The company manufactures and distributes an extensive portfolio of medical devices, consumables, and diagnostic solutions across vascular access, medication delivery, infection prevention, laboratory diagnostics, surgical instruments, and specialty medical equipment. Through the Medivance acquisition (2011), Bard offers the Arctic Sun™ Targeted Temperature Management system for precise patient temperature control in critical care settings. The company serves hospitals, healthcare systems, clinical laboratories, and other healthcare facilities with products spanning syringes and needles, catheters (central and peripheral), infusion systems, surgical mesh and grafts, diagnostic culture media, molecular testing systems, blood collection products, stents, and specialty equipment for urology, cardiology, gynecology, and interventional medicine. With thousands of SKUs across therapeutic areas including vascular surgery, gastrointestinal care, wound management, and microbiology solutions, Bard functions as a comprehensive B2B medical device and consumables supplier.

IncellDx is a molecular diagnostics and biotechnology company specializing in single-cell diagnostics for precision medicine. The company develops and manufactures diagnostic tools, reagents, probes, and antibodies for multiplex RNA in situ hybridization and protein detection. Its proprietary SUSHI (Simultaneous Ultrasensitive Signal-amplified Hybridization In Situ) platform enables simultaneous analysis of proteomic and genomic biomarkers within intact cells without complex sample preparation. Key offerings include HPV OncoTect™ kits for cervical cancer detection, mRNA probes (HPV E6/E7, CMV), monoclonal antibodies (anti-PD-L1, anti-CD45, anti-Pan Cytokeratin), hybridization core reagents, fixatives, cell cycle assays, and the incellPREP™ tissue single-cell suspension system. Products are available in multiple regulatory statuses: RUO (Research Use Only), GPR (General Purpose Reagents), ASR (Analyte Specific Reagents), CE-IVD (European In Vitro Diagnostic), and US-IVD. The company holds FDA registration, EU IVD compliance certification, and ISO 13485 quality management certification. Clinical applications target serious viral diseases including cervical cancer, HIV/AIDS, hepatitis, COVID-19, and other malignancies.

MagBio Genomics Inc. is a biotechnology company specializing in magnetic bead-based products for nucleic acid isolation and purification. Based in Gaithersburg, Maryland, the company develops comprehensive solutions for next-generation sequencing (NGS) workflows, genomic research, and clinical diagnostics. Their product portfolio includes DNA and RNA extraction kits, viral nucleic acid purification reagents, sample collection and stabilization products, post-PCR cleanup reagents, and NGS library preparation kits. MagBio's magnetic bead-based chemistry is compatible with both manual and automated laboratory platforms, supporting applications in cancer genomics, non-invasive prenatal testing (NIPT), viral diagnostics, and long-read sequencing. The company also provides OEM and custom solution development, along with distribution partnerships for life sciences research and clinical laboratories.

Revvity, Inc. is a comprehensive life science solutions provider serving academia, pharmaceutical, biotech, clinical laboratories, contract research organizations, and healthcare professionals globally. The company operates across the drug discovery-to-diagnostics continuum, delivering integrated workflows in translational multi-omics, biomarker identification, imaging, screening, detection, diagnosis, and informatics. Product portfolio includes high-content screening instruments (Opera Phenix, EnVision plate readers), optical imaging systems (IVIS), cell analysis instruments (Cellometer), sample preparation equipment (Omni Bead Ruptor Elite homogenizers), and laboratory automation (Fontus workstations, LabChip systems). Reagent brands encompass BioLegend antibodies and flow cytometry reagents, AlphaLISA and SureFire immunoassays, HTRF TR-FRET assays, Dharmacon RNAi and CRISPR tools, and custom oligonucleotide synthesis. Representative diagnostic and clinical service offerings include newborn screening (33M+ annual screens), immunodiagnostics via EUROIMMUN solutions (85M+ blood samples analyzed), infectious disease serology, TB testing (T-SPOT.TB, 20M+ tested since 2002), reproductive health solutions (maternal/prenatal testing, cell-free DNA analysis, preeclampsia management), and clinical genomics services (300M+ tests performed). Licensing portfolio covers gene expression, editing, and viral vector technologies including LentiBOOST and Pin-point base editing platforms. Revvity serves 94% of top 50 global pharma companies, maintains ~11,000 employees worldwide, and operates on-site manufacturing, viral vector engineering, preclinical oncology services, and clinical testing. Regulatory presence includes FDA and CE approvals across diagnostics and instruments. The company integrates acquisition-driven growth with organic R&D, supporting discovery through clinical deployment across life science workflows.

Roche Diagnostics is a global leader in in vitro diagnostic (IVD) instruments, assays, and laboratory systems for clinical chemistry, molecular diagnostics, pathology, and specialty testing. The company manufactures high-volume automated analyzer platforms including the cobas® c 703 for clinical chemistry (2,000 tests/hour), cobas® 5800 system for consolidated automation and integration, and Digital LightCycler® System for digital PCR applications. Product offerings span core lab chemistry, hematology, immunochemistry, mass spectrometry solutions (including Ionify® steroid assays), tissue diagnostics with ready-to-use oncology assays, and blood-based biomarker testing (e.g., pTau181 for Alzheimer's-related amyloid pathology). The organization serves laboratory professionals, clinicians, researchers, and patients across multiple laboratory settings. Roche maintains FDA clearances and 510(k) approvals for its analytical systems and assays, with CLIA moderate-complexity categorization for specialized tests. The company provides comprehensive support including eLabDoc document library access (800,000+ documents), e-learning platforms, PACE/CEU accredited training, and clinical education resources. Manufacturing and regulatory operations are supported from US facilities including Indianapolis headquarters.

Bosch Healthcare Solutions GmbH is a subsidiary of Robert Bosch GmbH specializing in innovative diagnostic solutions and medical technology. Founded in 2015 and based in Waiblingen, Germany, the company develops point-of-care and laboratory diagnostic devices for healthcare professionals. The flagship Vivalytic platform is a versatile PCR-based molecular diagnostics system delivering results in approximately 39 minutes for multiple infectious disease tests, including COVID-19, bacterial meningitis, MRSA, sexually transmitted infections, and Candida auris. The Vivatmo product line offers non-invasive breath analysis technology for measuring FeNO (fractional exhaled nitric oxide) in asthma management, available as both clinical and home-monitoring devices. With approximately 150 employees and €121.5 million in annual revenue, Bosch Healthcare Solutions focuses on creating user-friendly diagnostic products for hospitals, clinical laboratories, physicians' offices, and nursing homes. The company emphasizes rapid turnaround times, accessibility, and integration with healthcare workflows through strategic partnerships and continuous product innovation.

MedSupply Partners is a specialized distributor of laboratory equipment, consumables, and scientific products serving biotechnology, research, and clinical laboratories since 2003. The company supplies a comprehensive range of items including pipetting systems, centrifuges, cryogenic storage solutions, PCR plates, tissue culture products, molecular biology reagents, protective apparel, and infection control supplies. Their product portfolio spans from bench-top laboratory equipment (digital pipette controllers, mini centrifuges, water baths) to consumables (serological pipets, filter tips, culture dishes, biohazard disposal containers) and reagents (fetal bovine serum, DNA extraction kits). MedSupply Partners emphasizes quality and service reliability for research institutions, diagnostic laboratories, and biotech operations.

Empire Genomics is a molecular diagnostics company specializing in Fluorescence in Situ Hybridization (FISH) and Chromogenic in Situ Hybridization (CISH) probes for clinical diagnostics and research applications. Founded in 2006 by Dr. Norma J. Nowak and based in Depew, New York, the company originated from research at Roswell Park Comprehensive Cancer Institute. Empire Genomics offers a comprehensive portfolio of over 2,000 FISH probes optimized for cancer research, genetic testing across 200+ health conditions, and routine clinical diagnostics. Their product line includes manual and automated FISH probes, break-apart and fusion probes, single and dual-color probes, custom probe design services, and ancillary reagents. The company provides full-service FISH processing with rapid turnaround (next-day shipping for in-stock items; custom designs in two weeks). Empire Genomics supplies 44 of the top 50 US cancer centers and has sold over 1 million tests globally. Quality assurance includes BAC End Sequencing validation and access to a 645K+ clone library. Automation solutions include NeoPATH Pro for tissue, BioDot Cellwriter S for hematology, and ONCORE Pro for urine specimens.

Q-linea AB is a Swedish infection diagnostics company founded in 2008, specializing in rapid antimicrobial susceptibility testing (AST) systems for sepsis and bloodstream infection management. The company's flagship product, ASTar, is a fully automated, CE-IVD marked system that delivers antibiotic susceptibility profiles directly from positive blood cultures in approximately six hours—significantly faster than traditional methods that require 48+ hours. ASTar operates with minimal hands-on time (less than two minutes) and provides accurate MIC (minimum inhibitory concentration) values through controlled inoculum protocols, integrating with electronic medical records for seamless laboratory workflows. Q-linea addresses a critical clinical need: sepsis affects approximately 50 million people globally each year with 11 million deaths, making rapid diagnosis and appropriate antibiotic selection essential for patient survival. The company holds CE-IVD approval in Europe and FDA 510(k) clearance in the US, and collaborates with partners like Thermo Fisher Scientific for product commercialization. Q-linea's mission focuses on improving sepsis treatment outcomes while reducing unnecessary antibiotic use and combating antimicrobial resistance.

Cell Projects Limited is a UK-based molecular biology product designer and manufacturer serving life sciences research, medical diagnostics, and forensics markets since 2002. The company specializes in Electroporation, PCR, and qPCR kits manufactured to superior performance standards. Under the Isohelix brand, Cell Projects manufactures DNA/RNA collection systems from buccal and saliva samples, along with DNA stabilization and isolation kits that integrate into downstream molecular workflows. ISO 9001:2015 and ISO 13485:2016 certified, the company offers a complete design-to-manufacturing contract service for prototyping through final production. Cell Projects provides custom OEM development, clinical diagnostic project support, and collaborative research partnerships with leading universities. The company manufactures consumable plastics for PCR, electroporation, and sample storage applications.

Cyted Health is a Cambridge-based biotechnology company specializing in gastrointestinal molecular diagnostics for early detection and monitoring of esophageal conditions. Founded in 2020 as a University of Cambridge spinout, the company develops non-endoscopic diagnostic platforms that enable minimally invasive cell collection from the esophagus. The flagship product, EndoSign®, is an FDA-cleared capsule sponge device that provides safe, accessible esophageal sampling with full tissue coverage, significantly improving patient comfort and access compared to traditional endoscopy. Cyted Health combines proprietary biomarker discovery with AI-driven diagnostic tools to detect Barrett's Esophagus, esophageal neoplasia, and early-stage esophageal cancer. The company has completed over 35,000 tests through the UK National Health Service and operates CLIA-accredited laboratories in both the UK and US, serving healthcare systems with evidence-based screening and surveillance solutions for gastrointestinal malignancy prevention.

Lusis Biosciences is a California-based leader in qPCR assays and instruments for molecular diagnostics. The company specializes in VeraPoint qPCR assays and Q-Vera instruments designed for infectious disease detection across respiratory, urinary, sexually transmitted, gastrointestinal, and bloodborne pathogen applications. Lusis develops multiplexing technology-enabled reagents that simultaneously detect multiple targets, with a catalog of over 30 key products and hundreds of additional targets. The company also manufactures nucleic acid extraction reagents and sample processing solutions. Operating in over 160 countries with 10,000+ laboratory customers, Lusis combines integrated development and manufacturing capabilities with dedicated customer support and field application scientist consultation to deliver cost-effective, accessible molecular diagnostic solutions for clinical and research laboratories.

Nuclein, LLC is an in vitro diagnostics company specializing in rapid, point-of-care molecular diagnostic solutions for infectious diseases. Based in Austin, Texas and founded in 2017, the company develops portable, battery-powered PCR platforms that deliver lab-quality results in approximately 15 minutes without requiring traditional laboratory infrastructure. The flagship DASH Rapid PCR System is an FDA-cleared, CLIA-waived platform featuring an intuitive user interface, room-temperature cartridge storage, Wi-Fi and cloud connectivity, and multiplex-capable testing in a single cartridge. The system supports multiple sample types and has a compact footprint (15"D x 11"H x 4"W). Nuclein's current test menu includes the DASH SARS-CoV-2 & Flu A/B Test with dual FDA clearance, with plans to expand to additional infectious disease and condition testing. The platform is designed for healthcare settings, urgent care, clinics, and other point-of-care environments where rapid, accurate molecular diagnostics can inform immediate treatment decisions.

Infitek is a professional manufacturer of laboratory and medical equipment based in Shanghai, China, established in 2010. The company specializes in scientific instruments and medical devices for pharmaceutical, biopharmaceutical, and clinical laboratory applications. With 18 manufacturing facilities and certifications including ISO 9001 and ISO 13485, Infitek serves over 176 countries globally. The company's product portfolio encompasses incubators, refrigeration equipment, centrifuges, spectrophotometers, autoclaves, gas chromatographs, real-time PCR systems, hematology analyzers, and comprehensive sample preparation and analysis equipment. Infitek provides integrated solutions for pharmaceutical workflows, clinical diagnostics, and laboratory automation, complemented by purchasing and inspection services in China and comprehensive after-sales support.

Kashi Clinical Laboratories is a fully accredited clinical laboratory founded in 2006 and based in Portland, Oregon, specializing in high-quality molecular diagnostic testing, consultative services, and customized assay development. The laboratory offers comprehensive testing services including molecular genetic tests, HLA and transplant services, genomic and oncology services, virology, toxicology, pharmacogenetics (drug metabolism), and clinical pathology. Kashi provides pre- and post-transplant testing, SNP testing, KIR typing, HLA antibody screening and identification, engraftment monitoring, and environmental testing. The lab operates the Molecular Microscope™ (MMDx™) diagnostic system and emphasizes rapid turnaround times, EHR integration, and consultative partnerships with healthcare providers. Services span chemistry, immunology, hematology, coagulation, microbiology, and urinalysis, with a commitment to rigorous standards and personalized customer service.

Omega Bio-tek is a specialized nucleic acid purification solutions provider based in Norcross, Georgia, founded in 1998. The company develops and manufactures automated DNA and RNA extraction kits designed for clinical diagnostics, genomic research, biotechnology, and agricultural applications. Their product portfolio includes the Mag-Bind® family of magnetic bead-based kits for high-throughput extraction from diverse sample types including blood, saliva, tissue, environmental samples, FFPE specimens, and cell-free DNA. Omega Bio-tek specializes in automation-compatible extraction systems suitable for next-generation sequencing workflows, custom OEM solutions, and private-label manufacturing. The company serves research institutions, clinical laboratories, diagnostics companies, and biotechnology firms with ISO 9001 certified quality processes and comprehensive technical support including protocol optimization and automation platform integration.

BEE Medic is a global supplier of high-precision EEG-based medical equipment and software for neurofeedback, biofeedback, diagnostics, and EEG research. The company serves licensed mental health professionals, clinicians, and research institutions with FDA-cleared, modular systems developed in collaboration with clinical partners and research institutions. BEE Medic's product portfolio includes the NeuroAmp II amplifier family for EEG recordings, the Sync Box for ERP synchronization, and the Combi Sensor for biofeedback measurements. Software platforms such as Cygnet and BEE Lab support various neurofeedback training protocols and real-time brainwave feedback applications. The company operates as part of the BEE Group AG network with offices in the USA, Germany, Switzerland, and the UK, and provides comprehensive support including hands-on training courses, technical assistance, and clinical education to help practitioners implement neurofeedback therapies for ADHD, chronic pain, autism, PTSD, and other conditions requiring brain self-regulation.

Bio Plas, Inc. is a premier manufacturer of disposable plastic laboratory consumables serving clinical, industrial, educational, and governmental laboratory applications since 1977. Established as a Veteran Founded, Woman-Owned Small Business, the company produces a comprehensive range of FDA-compliant laboratory products including microcentrifuge tubes, pipette tips, PCR tubes, inoculation systems, and specialty histology containers. All products are manufactured in the USA under rigorous California and FDA GMP guidelines and licensed by both state and federal authorities. Bio Plas operates exclusively through a B2B distributor network, ensuring consistent quality assurance and prompt delivery to healthcare and research institutions. The company maintains BioSecure Act compliance and emphasizes premium quality combined with exceptional customer service.

EUROIMMUN US Inc. is the North American subsidiary of Euroimmun, a leading German manufacturer of medical laboratory diagnostics founded in 1987. Operating in 18 countries with over 3,400 employees globally, the company specializes in innovative test systems, software, and automation solutions for diagnosing autoimmune diseases, infectious diseases, allergies, neurodegeneration, endocrinology, bone metabolism, and genetic analyses. Headquartered in Mountain Lakes, NJ, EUROIMMUN US supplies clinical laboratories with advanced immunodiagnostic reagents, microarray technologies, and chemiluminescence immunoassay (ChLIA) automation platforms. The company produces comprehensive antibody detection test systems and maintains ISO certifications, serving laboratory medicine professionals with high-quality, standardized diagnostic solutions for autoimmunity, infection control, and specialized clinical parameters.

BioGX, Inc. is a clinical molecular diagnostics manufacturer headquartered in Birmingham, Alabama, with additional offices in Dallas, Texas and Amsterdam, The Netherlands. The company designs and manufactures extraction-free, lyophilized molecular diagnostic reagents and assays for RT-PCR testing, delivered as one-tube, Sample-Ready™ formulations. BioGX specializes in producing Laboratory Developed Tests (LDTs) and Open Source Reagents (OSRs) that enable clinical laboratories to rapidly expand their molecular diagnostics portfolios without requiring reagent extraction steps, reducing turnaround time and operational complexity. Primary product lines include Xfree™ direct RT-PCR assays for SARS-CoV-2, influenza A/B, RSV, monkeypox, HSV-1/HSV-2, VZV, syphilis (Treponema pallidum), Group A Streptococcus, and Mycoplasma pneumoniae. The company also offers Sample-Ready™ PCR assays for Candida auris and multi-platform reagents compatible with leading real-time PCR instruments (Bio-Rad CFX series, Applied Biosystems QuantStudio 5, Bio-Rad CFX96/384 Touch, ABI 7500 Fast Dx). BioGX detects a comprehensive range of bacterial targets (including Neisseria gonorrhoeae, Chlamydia trachomatis, Mycoplasma genitalium, and multiple Gram-negative and Gram-positive pathogens), viral targets, fungi (Candida species), and antimicrobial resistance markers (mecA, vanA/B/C, KPC, NDM, OXA-48). The company holds FDA Emergency Use Authorization (EUA) for Xfree™ COVID-19 Direct RT-PCR and CE-IVD marking for its international product portfolio. BioGX manufactures reagents optimized for high-throughput 96- and 384-well plate formats and fully automated systems such as BD MAX™. The company serves clinical laboratories, hospital systems, diagnostic reference laboratories, and public health agencies globally. Founded in 2007, BioGX combines formulation chemistry with regulatory expertise to enable laboratories of all sizes to implement rapid molecular diagnostics.

LGC Group is a global leader in life science tools, diagnostics, and analytical measurement solutions headquartered in London, operating across 14 countries with products sold in over 180 markets. Established in 1842 and employing approximately 3,800 professionals (including ~1,100 with advanced degrees), LGC serves clinical diagnostics, biopharma, contract research, and academic institutions. The company is recognized as the UK National Measurement Institute for chemical and bio measurement with extensive international quality accreditations. LGC operates through multiple specialized divisions: Clinical Diagnostics providing end-to-end diagnostic solutions; Biosearch Technologies offering GMP/GLP/ISO-compliant services in infectious diseases, oncology, and prenatal testing; LGC Standards delivering research chemicals, analytical standards, proficiency testing, and PFAS portfolios; Supply Chain Assurance supporting food and sports nutrition industries via BRCGS and INFORMED certifications; Nucleic Acid Therapeutics covering oligonucleotide and mRNA-based therapeutic development and production; and National Laboratories supporting UK public health initiatives and government measurement standardization. The company advances science for a safer world by ensuring safety of food, medicines, water, and supporting precision medicine advancement.

bioMérieux is a global in vitro diagnostics leader headquartered in France, with significant US operations. The company manufactures and distributes comprehensive diagnostic solutions for clinical microbiology, molecular pathology, blood culture detection, immunoassays, and rapid point-of-care testing. Core competencies span microbial identification and antimicrobial susceptibility testing (ID/AST), sepsis diagnosis and management, infectious disease detection (respiratory pathogens, gastrointestinal pathogens), and blood culture systems. Key product platforms include BIOFIRE® FILMARRAY® multiplex PCR systems, VITEK® MS PRIME mass spectrometry, BACT/ALERT® VIRTUO® blood culture automation, and VIDAS® immunoassay analyzers. The company also serves pharmaceutical and food safety markets with quality control and environmental monitoring solutions. bioMérieux addresses critical clinical challenges including antimicrobial resistance (AMR) stewardship, rapid sepsis identification, and respiratory infection diagnostics. Offerings span hospital laboratories, point-of-care settings, and industrial applications. The company emphasizes diagnostic-driven clinical decision support, workflow automation, and integrated laboratory information management. Manufacturing includes automated detection systems, rapid molecular platforms, and MALDI-TOF mass spectrometry instruments. US operations distribute test kits, reagents, and instruments through multiple channels including direct sales and the bioMérieux eShop. The company holds multiple regulatory clearances including FDA 510(k) approvals and CE marking for diagnostic instruments and test kits.

Globe Scientific, Inc. is a New Jersey-based manufacturer and supplier of laboratory consumables, glassware, plastics, and analytical instruments serving clinical laboratories, research institutions, and life science facilities. The company offers a comprehensive product portfolio including DiamondPure™ chromatography and headspace vials for HPLC and GC workflows, RingSeal™ cryogenic storage vials, TransferTop™ urine collection and direct transfer cups, and GenesisBPS blood collection and processing systems. Product lines include borosilicate glass culture tubes (ISO 9001:2008 certified), Diamond® SureGro™ cell and tissue culture plastics, Diamond Shell PCR plates, microcentrifuge tubes with locking snap caps (certified RNase, DNase, pyrogen, ATP, and human DNA free), vacuum filtration systems, pipette tips, laboratory film sealants, and microscopy equipment including Euromex iScope and NexiusZoom stereo microscopes. The company manufactures or sources analytical balances, tube rockers, and sample storage solutions. Products are marketed under proprietary brands including DiamondPure, Diamond Essentials, Diamond APEX, Diamond PosiStop, and Seal-R-Film. Globe Scientific serves educational institutions, industrial research labs, pharmaceutical companies, and clinical diagnostic facilities. The company maintains international distribution partnerships in Europe and globally through dedicated sales teams.

Oxford Gene Technology (OGT) is a precision genomics company specializing in molecular diagnostics for clinical and research laboratories. The company develops and manufactures hybridization-based FISH (fluorescence in situ hybridization), NGS (next-generation sequencing), and array-based genomic solutions for haematological malignancies, solid tumours, cytogenetics, and rare disease detection. OGT's primary product portfolio includes CytoCell FISH probes, SureSeq NGS panels, and CytoSure arrays. Recent offerings include the SureSeq Myeloid MRD Plus NGS Panel for minimal residual disease detection in acute myeloid leukaemia, and the FDA-authorized CytoCell KMT2A Breakapart FISH Probe Kit PDx as a companion diagnostic for KMT2A-rearranged acute leukaemia. OGT provides end-to-end support from assay design through clinical implementation, including precision medicine partnering for clinical trial and companion diagnostic development. The company serves clinical diagnostic laboratories, research institutions, and oncology centers globally, with established partnerships and customer bases across North America, Europe, and international markets. OGT's technical support is provided by personnel with laboratory backgrounds, supporting implementation of test workflows and biomarker interrogation. The company holds FDA authorizations for companion diagnostics and operates under clinical laboratory standards for genomic testing.

QuidelOrtho Corporation is a global in vitro diagnostics company providing diagnostic solutions across clinical laboratory, transfusion medicine, molecular testing, and point-of-care applications. The company offers over 550 assays across multiple testing modalities including real-time PCR, rapid lateral-flow immunoassays, automated immunohematology systems, and benchtop analyzers. Key product platforms include LYRA™ real-time PCR assays (open platform molecular testing), QUICKVUE™ rapid lateral-flow tests for infectious diseases and point-of-care diagnostics, TRIAGE™ System for point-of-care immunoassays, VITROS™ benchtop clinical chemistry systems, SOFIA™ 2 Analyzer for rapid diagnostics, ORTHO VISION™ Swift automated blood bank analyzers, ORTHO™ Workstation semi-automated immunohematology analyzer, and ORTHO OPTIX™ Reader for transfusion lab testing. The company serves clinical laboratories, hospitals, point-of-care settings, and home-testing markets in 140+ countries. QuidelOrtho recently completed acquisition of Lex Diagnostics, expanding its diagnostic portfolio. The company manufactures diagnostic instruments, reagents, and assays for infectious disease detection (virology, molecular, immunoassay), blood banking, clinical chemistry, and specialty testing. Products are regulated as in vitro diagnostic devices under FDA and international standards.

EntroGen, Inc. is a molecular diagnostics company specializing in oncology and personalized medicine solutions. The company develops and manufactures FDA-approved and research-use-only (RUO) PCR-based assays for cancer biomarker detection, companion diagnostics, and minimal residual disease (MRD) monitoring. Core product portfolio includes the CRCdx® RAS Mutation Detection Kit (FDA-approved companion diagnostic for KRAS and NRAS mutations in colorectal cancer), NPM1 One-Step MRD Kit for acute myeloid leukemia detection, DPYD Genotyping Kit for pharmacogenomic assessment, and Microsatellite Instability (MSI) Detection Kit. EntroGen manufactures the Benchbot® 4800 laboratory automation platform designed to streamline workflow from sample preparation to PCR plate setup in four steps. The company offers three integrated product lines: automation equipment, molecular reagents/assays, and analysis software. All products are manufactured to ISO 13485 quality standards. EntroGen serves clinical laboratories, hospital pathology departments, and oncology centers globally, supporting treatment decision-making through molecular testing. The company participates in industry conferences including the World Clinical Biomarkers & Companion Diagnostics Summit, indicating active engagement in the molecular diagnostics and precision oncology markets.

Alkali Scientific is a life sciences supplier serving biotech, pharmaceutical, research, and clinical laboratory markets. The company distributes laboratory consumables, molecular biology reagents, and specialized equipment to over 5,200 biotech and pharma companies and 9,800+ research labs and hospitals, including major institutions such as NIH, Cleveland Clinic, Stanford University, MD Anderson Cancer Center, Johns Hopkins, and Pfizer. Product portfolio includes qPCR reagents (Radiant brand), PCR tubes (ProCycle brand), pipette tips (PurePoint brand), cell culture flasks (CellPro brand), and nitrile examination gloves (UltraSOFT 5000 brand). The company operates an e-commerce platform with same-day shipping capabilities on high-volume items. Services include product cross-referencing tools to match competitor products and a product submission system. Target markets encompass academic research institutions, clinical diagnostics, pharmaceutical development, and biotech manufacturing. The company maintains preferred vendor relationships with major health systems and research universities across the United States.

Tetracore, Inc is a diagnostics innovator specializing in the development and manufacture of reagents, assays, and portable instruments for the detection of infectious diseases and bioterrorism threat agents. Founded over 20 years ago and headquartered in Rockville, MD, the company serves domestic preparedness, forensic biology, human health, and veterinary sectors. Primary product lines include the T-COR 8 Real-Time PCR Thermocycler, a portable system for rapid on-site detection of biothreat, veterinary, and environmental samples; BioThreat Alert Reader VII, a portable lateral flow assay (LFA) reader; BioThreat Alert Rapid Test Strips for immunological and molecular detection of biological threat agents; real-time PCR kits and reagents for infectious disease and animal disease detection; and FlexImmArray multiplex assays for arbovirus and pathogen detection on Luminex and Bio-Plex platforms. The company also produces EZ-SARS-CoV-2 RT-PCR testing kits and VetAlert real-time PCR assays for animal health applications, including African Swine Fever monitoring. Tetracore holds ISO 9001, ISO 13485, and ISO/IEC 17025 accreditation certifications, demonstrating quality management and laboratory competence. The company's products are designed for rapid deployment in field and laboratory settings, emphasizing actionable results and ease of use for emergency response and disease surveillance.

DiaSorin Molecular LLC is a world leader in laboratory diagnostics, specializing in immunodiagnostics and molecular diagnostics. The company develops and manufactures in vitro diagnostic systems for detecting antibodies, antigens, and pathogens in biological specimens. Core product lines include the LIAISON® immunodiagnostic platform for infectious disease detection (tuberculosis, hepatitis, viral infections), Simplexa® molecular assay kits for direct pathogen detection (COVID-19, influenza, RSV, cytomegalovirus, herpes simplex virus), and the LIAISON NES® CLIA-waived rapid molecular test delivering results in approximately 15 minutes. Additional offerings include LIAISON® MeMed BV® for bacterial-viral differentiation, LIAISON® QuantiFERON®-TB Gold Plus II for TB detection, and LIAISON® BRAHMS PCT® for infection triage. The company also operates the Luminex division, providing xMAP® multiplex assay platforms and xMAP INTELLIFLEX® systems for research and clinical diagnostics, along with custom assay design and development services. DiaSorin serves clinical laboratories, hospitals, and research institutions globally. The company maintains regulatory compliance with FDA clearances and CLIA waivers for its diagnostic systems. Manufacturing and service capabilities span immunoassay automation, molecular PCR testing, and multiplex diagnostic platforms.

Bio-Rad Laboratories is a global life science and clinical diagnostics company that manufactures and distributes instruments, reagents, consumables, controls, and data management software for research and diagnostics laboratories. The company serves academic research, industrial bioprocessing, and clinical diagnostic markets with a diverse product portfolio spanning PCR and qPCR systems (including proprietary ddPCR digital droplet technology), Western blotting reagents and systems, blood typing and screening products, immunoassay controls, antibodies, cell counting equipment, gel documentation and imaging systems, and process separation solutions for biopharmaceutical purification. Bio-Rad's offerings extend to quality control solutions, specialized testing kits for oncology mutation detection and infectious disease screening, and classroom education products. The company maintains robust e-commerce capabilities including PunchOut procurement integration, quick ordering, order status tracking, and document library management for B2B customers. Product lines include the QX200/QX600 ddPCR platforms, CFX Real-Time PCR systems, TC20 automated cell counters, ChemiDoc imaging systems, and specialized molecular detection kits. Bio-Rad serves clinical laboratories, research institutions, biotech firms, and educational organizations globally with regulatory credentials supporting ISO and FDA compliance across its diagnostics and instrument portfolios.

Twist Bioscience Corporation is a US-based synthetic biology company specializing in DNA-based research tools and services. The company operates a proprietary semiconductor-based synthetic DNA manufacturing platform utilizing high-throughput silicon technology for miniaturized chemistry and cost-efficient DNA synthesis. Core product portfolio includes synthetic genes (clonal genes, gene fragments, gene pools, vectors), oligonucleotide pools (cloned and uncloned), next-generation sequencing (NGS) target enrichment solutions, library preparation kits (including TrueAmp Library Prep Kit and PCR-free WGS kits), variant libraries (combinatorial, site saturation, spread-out low diversity), and synthetic controls for infectious disease and liquid biopsy applications. The company also offers comprehensive antibody discovery and development services including in vitro phage display, in vivo discovery using Diversimab technology and humanized transgenic mice, antibody characterization (SPR, developability assessment, functional assays), and optimization services including AI/ML-driven affinity maturation and in silico humanization. Twist Service Lab provides outsourced sequencing services, and the company offers automation solutions and API-based procurement integration. Target markets include academic research, pharmaceutical drug discovery, cancer research, infectious disease research, agricultural biotechnology, and clinical diagnostics. The platform enables researchers to access customizable gene synthesis at varying scales, perform high-confidence genomic screening, and conduct precision variant detection across NGS workflows.

MiraVista Diagnostics is a CAP- and CLIA-certified clinical reference laboratory specializing exclusively in diagnostic testing for serious fungal infections. Founded in 2002 by renowned infectious disease scientist Lawrence Joseph Wheat, MD, the company has established itself as the leading authority in mycological diagnostics. MiraVista processes over 100,000 diagnostic tests annually for blastomycosis, histoplasmosis, cryptococcosis, aspergillosis, coccidioidomycosis, and beta-D glucan detection across multiple specimen types including bronchoalveolar lavage (BAL) fluid. The laboratory offers both antigen-detection methods (EIA, latex agglutination) and molecular diagnostic assays, including the newly available MVista® Fungal PCR Panel for pulmonary fungal pathogen multiplex detection. The company provides same-day testing with prompt turnaround times and employs experienced infectious disease specialists. With over 1,000 peer-reviewed publications in leading infectious disease and clinical laboratory journals, MiraVista serves hospital laboratories, clinicians, and researchers requiring high-complexity fungal serology and molecular diagnostics. The organization also operates a parallel veterinary diagnostic division (MiraVistaVets.com). Regulatory compliance includes CAP and CLIA certifications, positioning the laboratory for clinical and reference testing across academic medical centers, community hospitals, and specialized infection control programs.

Targeted Genomics is a family-owned molecular diagnostics company specializing in celiac disease genetic risk assessment. The company develops and offers the GlutenID™ test, an FDA-cleared at-home saliva-based genetic test that identifies HLA-DQ2 and HLA-DQ8 genotypes associated with celiac disease risk. The test is designed as a universal triage tool to distinguish at-risk individuals from those who can rule out celiac disease. Founded and led by Dr. Shelly Gunn, MD, PhD, a board-certified pathologist with expertise in molecular diagnostics and genomic analysis, Targeted Genomics partners with PacificDX, a CAP/CLIA-certified laboratory in Irvine, CA, for sample processing and analysis. The company also offers complementary celiac disease testing services including the Celiac Disease Panel (antibody testing) and CeliacDx Consult (expert pathology review). Testing workflow involves at-home saliva collection via cheek swab, mail-in sample submission with prepaid shipping, laboratory processing, and secure email delivery of results with actionable next steps. The company maintains strict privacy controls—only HLA genotypes are interrogated, genomic data is stored securely for two years per CAP requirements, and data is never sold or shared with third parties. Targeted Genomics serves consumers, families with celiac history, and healthcare providers seeking efficient genetic screening to guide subsequent antibody and biopsy testing in celiac disease diagnosis.

Laboratory Corporation of America Holdings (Labcorp) is a global leader in laboratory services headquartered in Burlington, North Carolina. Operating in approximately 100 countries with over 70,000 employees, Labcorp performs more than 700 million tests annually and generates $13.01 billion in revenue. The company provides comprehensive clinical diagnostics, drug development support, and specialized testing including oncology, rare diseases, and genomic sequencing. Labcorp's integrated platform connects diagnostics to biopharma development, supporting healthcare providers, researchers, and investigators. Key offerings include AI-powered diagnostic assistance tools, real-world data platforms for drug development, genetic testing services (including Invitae), nonclinical research, central laboratory services, and clinical trial support. The company serves patients, healthcare providers, health systems, managed care organizations, and biopharmaceutical companies. Over 75% of new drugs approved by the FDA have been supported by Labcorp's services.

Biodesix is a CLIA-certified and CAP-accredited life sciences diagnostics company specializing in AI-driven, blood-based diagnostic tests for lung cancer and related respiratory diseases. Founded in 2005 and publicly traded since 2020, the company combines multi-omic approaches—including genomics, proteomics, and advanced mass spectrometry—with proprietary artificial intelligence algorithms to deliver personalized diagnostic solutions. Flagship offerings include the Nodify Lung Nodule Risk Assessment and IQLung Strategy Tests, which guide clinical decision-making for lung nodule management and non-small cell lung cancer treatment selection. Beyond clinical diagnostics, Biodesix operates a robust biopharma services division providing translational research, biomarker discovery, companion diagnostic development, and clinical trial support to leading biopharmaceutical and research institutions. The company's liquid biopsy technology platform enables non-invasive risk stratification and prognostic assessment, addressing a critical clinical need in early cancer detection and precision oncology.

Promega Corporation is a global life science reagent and instrument manufacturer specializing in assays, reagents, and detection systems for research, drug discovery, clinical diagnostics, and forensic applications. The company develops bioluminescent reporter systems (NanoLuc® Luciferase, firefly luciferase), qPCR and RT-qPCR master mixes (GoTaq® systems), cell viability and apoptosis assays (CellTiter-Glo®, Caspase-Glo®), kinase selectivity profiling platforms (NanoBRET® systems), and imaging instrumentation (GloMax® Galaxy bioluminescence imager). Primary markets include small-molecule drug discovery, cell and gene therapy development, clinical research and molecular diagnostics, human identification (forensic DNA analysis), and academia. Manufacturing and R&D operations in Madison, Wisconsin are ISO 9001 (Quality Management Systems) and ISO 14001:2015 (Environmental Management Systems) certified. Products are manufactured under stringent quality control standards suitable for regulated clinical and diagnostic applications. Technical support and customer service resources include protocols, certificates of analysis, safety data sheets, and dedicated technical services scientists. The company serves pharmaceutical, biotech, clinical laboratory, forensic, and academic research markets globally.

ACON Laboratories, Inc. is a US FDA-registered global medical device manufacturer specializing in point-of-care testing (POCT) and immunoassay products. Headquartered in San Diego, California, the company develops and manufactures diagnostic solutions across four primary product lines: Point of Care, Immunoassays, Molecular Diagnostics, and Animal Health. Products serve hospitals, clinical laboratories, physician offices, blood banks, pharmacies, and veterinary clinics worldwide. The On Call® Blood Glucose Meter Family is designed for glucose monitoring and diabetes management. Mission® brand includes urine reagent test strips, urine analyzers, and handheld devices for cholesterol, coagulation, and hemoglobin measurement. HealthyMe® provides urinary tract infection (UTI) detection reagent strips. Flow flex® is the newest lateral flow rapid testing brand, offering multiplexed home tests including the recently FDA 510(k)-cleared Flow flex® Plus RSV + Flu A/B + COVID multiplex rapid antigen test for ages 6 months and up. The company's ACON brand offers lateral flow rapid tests for pregnancy, cancer markers, and infectious disease screening, including SARS-CoV-2 antibody and antigen tests. Distinct® provides pregnancy rapid tests using qualitative chromatographic immunoassays. Foresight® offers allergen immunoblot testing for 30 allergens on a single strip. Promotor® provides nucleic acid extraction systems and PCR quantitative test kits for HBV, HCV, HPV 16/18, HPV genotyping, tuberculosis, and HLA-B27. CentriVet® serves veterinary diagnostics with dual ketone/glucose meters and urine reagent strips. ACON maintains US FDA registration, provides contract manufacturing and OEM services, and holds multiple FDA 510(k) clearances for its diagnostic products.

Bioneer Corporation is a life-science research supplier headquartered in Oakland, CA, specializing in molecular biology reagents, enzymes, nucleic acid synthesis and preparation kits, and laboratory instruments. The company manufactures and distributes a comprehensive portfolio including DNA/RNA amplification and prep reagents (AccuPrep kits for genomic DNA, mRNA, plant genomic DNA, and universal RNA), DNA/RNA synthesis reagents and phosphoramidites, polymerases and enzymes, oligonucleotides, RNAi products (siRNA and miRNA), gene synthesis services, protein expression and purification reagents, molecular markers and ladders, plastic consumables, and specialized instruments. Bioneer also offers drug target and toxicity identification services (GPScreen) and maintains a yeast genome-wide S. pombe knock-out library for functional genomics research. The company serves academic research institutions, biotechnology firms, pharmaceutical companies, and contract research organizations in North America. Products are supported by technical protocols, material safety data sheets, reference literature, and application notes. Bioneer maintains both US operations in Oakland and international headquarters in Daejeon, South Korea. The company provides customer support via toll-free phone, email, and direct technical assistance for product troubleshooting and applications development.

Spectrum Solutions (Spectrum Health Science) is a vertically integrated medical device and diagnostics manufacturer specializing in salivary diagnostic solutions and non-invasive testing platforms. Operating from Utah with ~840 employees and $213M+ annual revenue, the company offers end-to-end capabilities spanning medical device engineering, molecular diagnostics development, chemical formulation, contract manufacturing, specialized packaging, and global fulfillment. Its flagship SimplyTest® brand delivers direct-to-consumer and clinical-grade salivary tests for oral health, periodontal disease, HPV screening, women's health, and functional medicine markers. The company operates a CAP-accredited, CLIA-certified laboratory and a 50-state licensed pharmacy, enabling national scalability. ISO 13485 certified, Spectrum Solutions serves dental practices, healthcare providers, and DTC channels with companion diagnostics, genomic testing, and custom microarray development. The company is positioned as a single-source provider for IVD (in vitro diagnostics) innovation, particularly in salivary-based molecular testing.

Pro-Lab Diagnostics is a Canadian manufacturer and global distributor of clinical diagnostic test kits, laboratory products, and immunodiagnostic reagents. Founded in 1974 and based in Toronto, Ontario, the company serves 45 countries and 15,000 hospitals with over 50 years of expertise. Pro-Lab specializes in clinical microbiology, women's health, molecular diagnostics, and general laboratory supplies. Key product lines include the original TransVelope™ specimen transport bag, AmnioTest™ Nitrazine Swab for OB-GYN testing, Prolex™ Latex Agglutination tests, Microbank® organism storage systems, Prolisa™ ELISA assays, and OptiGene molecular diagnostic solutions. The company provides customized immunodiagnostic solutions, point-of-care training programs, and private labeling services for pharmaceutical manufacturers and research organizations. Certified to ISO 13485:2016 and FDA-registered, Pro-Lab delivers high-quality laboratory diagnostics to hospitals, clinical laboratories, obstetric facilities, and research institutions worldwide.

Invivoscribe is a San Diego-based molecular diagnostics company founded in 1995, specializing in precision oncology testing and personalized molecular medicine for hematologic malignancies. The company develops and manufactures CE-marked in vitro diagnostic assays, research-use-only (RUO) assays, analyte-specific reagents (ASRs), and DNA/RNA controls under ISO 13485 design control. Core product lines include next-generation sequencing (NGS) panels for clonality testing (B- and T-cell), minimal residual disease (MRD) assays (LymphTrack®, LeukoStrat® FLT3-ITD and NPM1), and companion diagnostics (CDx) for precision oncology drug therapies. Invivoscribe operates LabPMM®, a CAP-accredited clinical laboratory with multiparametric flow cytometry and molecular testing services, serving clinical laboratories, pharmaceutical companies, and researchers across 160+ countries and 700+ laboratories worldwide. The company also provides bioinformatics software, custom assay development, and turn-key CDx collaboration for pharmaceutical partners, emphasizing regulatory expertise and streamlined drug approval pathways.

Sinochips Diagnostics is a CLIA & CAP-accredited clinical laboratory specializing in advanced molecular testing for precision medicine and diagnostics. The company offers pharmacogenomics testing (DNA-based medication optimization), infectious disease panels (respiratory pathogens, UTI), and biomarker analysis with rapid turnaround times. Services include multiplex PCR panels, serology testing, and diagnostic rRT-PCR assays, primarily serving healthcare providers, clinics, and hospitals. Sinochips combines state-of-the-art molecular technology with streamlined sample collection, processing, and secure online result portals to enable data-driven clinical decision-making.

Werfen (formerly Immucor, Inc.) is a global leader in specialized diagnostics for transfusion and transplantation medicine. The company manufactures a comprehensive portfolio of serology-based reagents, automated instruments, and molecular diagnostic products serving blood banks, transfusion services, clinical laboratories, reference laboratories, donor centers, and transplant programs worldwide. Core product lines include: (1) Transfusion diagnostics—blood typing, antibody screening and identification, platelet serology, and HLA donor screening assays; (2) Transplant diagnostics—HLA typing kits (including NanoTYPE® HLA-11 Plus), HLA and non-HLA antibody detection products, and post-transplant monitoring assays; and (3) Coagulation diagnostics for heparin-induced thrombocytopenia (HIT) and thrombotic thrombocytopenic purpura (TTP) detection. Signature automated platforms include the NEO® and NEO Iris® systems for immunohematology automation, and Echo Lumena® for antibody identification with enhanced imaging. The company acquired Omixon (Hungary) to expand HLA typing capabilities. Werfen operates globally across hospital blood banks, reference laboratories, and transplant centers, leveraging customer-centric support with field representatives who possess transfusion and transplant technical expertise. The company emphasizes regulatory compliance, quality assurance, and comprehensive technical and educational support to streamline laboratory workflows and improve patient outcomes in transfusion and transplant medicine.

Biomiga, Inc. is a San Diego-based biotech research and manufacturing company specializing in nucleic acid extraction, purification, and PCR-based diagnostic products. Core product lines include the MgPure family of automated DNA/RNA extraction kits designed for diverse sample types: pathogenic, blood, saliva, circulating cell-free DNA, and formalin-fixed paraffin-embedded (FFPE) tissue. The company manufactures DNA/RNA size-selection beads offering superior yield (10–20% better than benchmarks) at competitive pricing, with full USA manufacturing and OEM customization capability. MgPure Seq DTR beads support sequencing workflows with >800 bp average reading lengths, available in manual or automated formats compatible with major platforms (Kingfisher Flex, Biomek, Hamilton, and others). Biomiga offers comprehensive real-time PCR detection assays targeting infectious disease panels, including respiratory pathogen panels (RPP), sexually transmitted infections (STI), gastrointestinal pathogens, women's health, wound infection markers, and nail fungal detection. The company also provides customized services for gene synthesis, cell line construction, protein expression, lentivirus packaging, and next-generation sequencing. FDA-registered facility with ISO 9001:2015 certification. All extraction protocols are fully validated for automation on industry-standard platforms. The company emphasizes in-house manufacturing control, 24/7 customer support, and R&D-driven product development.

Mel-Mont Medical Inc is a clinical diagnostics and molecular technology company specializing in HPV-related cancer detection and prevention. The company develops patented, non-invasive self-sampling medical devices coupled with proprietary comprehensive molecular testing platforms for early identification of high-risk human papillomavirus (HR-HPV) infections. The company operates three primary product divisions: (1) Medical Devices—user-friendly, patented devices for HPV-related cancer prevention; (2) In Vitro Diagnostics (PreTect division)—ISO 13485-certified molecular assays for nucleic acid amplification and HPV-mRNA testing with proprietary laboratory services; (3) Sample Preparation Reagents—molecular testing reagents and transport media for sample handling. Mel-Mont Medical maintains a rigorous R&D pipeline following a six-stage development methodology: concept identification, usage characterization, design and development, pilot production and validation, regulatory prelaunch monitoring, and market launch with post-market surveillance. The company conducts preclinical and clinical trials to validate devices before market introduction and emphasizes clinically proven molecular biology technologies. Products are manufactured in compliance with applicable standards. The company serves international markets including the United States, Mexico, Spain, Norway, and Colombia, with distribution and manufacturing partnerships in select regions.